From: OMERACT-based fibromyalgia symptom subgroups: an exploratory cluster analysis
Variables | Cluster 1b(n = 116) | Cluster 2c(n = 154) | Cluster 3d(n = 100) | Cluster 4e(n = 108) | P-valuef |
---|---|---|---|---|---|
Age, yr | 49.3 (15.2) | 47.4 (13.2) | 45.1 (12.1) | 43.7 (10.9) | 0.0074 |
BMI, kg/m2 | 29.1 (6.7) | 31.3 (8.5) | 29.7 (8.3) | 30.3 (7.2) | 0.14 |
FM research survey | Â | Â | Â | Â | Â |
WPI | 12.1 (3.6) | 13.2 (3.7) | 12.9 (3.6) | 14.3 (3.3) | <0.0001 |
SS | 7.1 (1.7) | 8.1 (1.7) | 9.3 (1.5) | 9.6 (1.5) | <0.0001 |
SF-36 | Â | Â | Â | Â | Â |
Physicalg | 36.3 (7.4) | 26.2 (7.0) | 31.7 (6.8) | 24.6 (5.7) | <0.0001 |
Mentalg | 45.0 (10.6) | 42.6 (10.2) | 29.7 (9.8) | 31.6 (9.8) | <0.0001 |
FIQ total | 37.9 (10.7) | 61.3 (10.8) | 62.4 (9.2) | 79.3 (7.9) | <0.0001 |
Medications | Â | Â | Â | Â | Â |
SNRI | 26 (22.4) | 37 (24.0) | 34 (34.0) | 48 (44.4) | 0.0007 |
TCA | 12 (10.3) | 20 (13.0) | 14 (14.0) | 10 (9.3) | 0.66 |
α-2-δ ligand | 23 (19.8) | 44 (28.6) | 24 (24.0) | 32 (29.6) | 0.29 |
SSRI | 22 (19.0) | 36 (23.4) | 29 (29.0) | 26 (24.1) | 0.39 |
Othersh | 17 (14.7) | 18 (11.7) | 23 (23.0) | 18 (16.7) | 0.11 |
Any medication that could be used to treat depression (above) | 72 (62.1) | 105 (68.2) | 76 (76.0) | 83 (76.9) | 0.0488 |
Tramadol | 12 (10.3) | 22 (14.3) | 15 (15.0) | 20 (18.5) | 0.38 |
Skeletal muscle relaxants | 20 (17.2) | 43 (27.9) | 24 (24.0) | 33 (30.6) | 0.10 |
Opioids | 21 (18.1) | 51 (33.1) | 28 (28.0) | 57 (52.8) | <0.0001 |
Benzodiazepines | 22 (19.0) | 32 (20.8) | 49 (49.0) | 48 (44.4) | <0.0001 |
Sleep aids | 26 (22.4) | 48 (31.2) | 30 (30.0) | 39 (36.1) | 0.16 |
Total number of medications, mean (±SD) | 1.9 (1.6) | 2.5 (1.9) | 3.1 (2.1) | 3.4 (2.0) | <0.0001 |
Use of one or more symptom-modifying medication | 92 (79.3) | 131 (85.1) | 89 (89.0) | 100 (92.6) | 0.0272 |